<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.fiercepharma.com" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>Zyprexa</title>
 <link>http://www.fiercepharma.com/tags/zyprexa</link>
 <description></description>
 <language>en</language>
<item>
 <title>Under pharma earnings, basic problems</title>
 <link>http://www.fiercepharma.com/story/under-pharma-earnings-basic-problems/2008-04-23?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description> You&#039;ve heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/under-pharma-earnings-basic-problems/2008-04-23&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/under-pharma-earnings-basic-problems/2008-04-23#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/big-pharma">Big Pharma</category>
 <category domain="http://www.fiercepharma.com/tags/generic-competition">generic competition</category>
 <category domain="http://www.fiercepharma.com/tags/patent-expirations">patent expirations</category>
 <category domain="http://www.fiercepharma.com/tags/pharma-stocks">Pharma Stocks</category>
 <category domain="http://www.fiercepharma.com/tags/protonix">Protonix</category>
 <category domain="http://www.fiercepharma.com/tags/singulair">Singulair</category>
 <category domain="http://www.fiercepharma.com/tags/tamiflu">Tamiflu</category>
 <category domain="http://www.fiercepharma.com/tags/vytorin">Vytorin</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Wed, 23 Apr 2008 06:59:55 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8891 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>Emerging markets drive global growth</title>
 <link>http://www.fiercepharma.com/story/emerging-markets-drive-global-growth/2008-04-16?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description> Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/emerging-markets-drive-global-growth/2008-04-16&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/emerging-markets-drive-global-growth/2008-04-16#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/amgen">Amgen</category>
 <category domain="http://www.fiercepharma.com/tags/aranesp">Aranesp</category>
 <category domain="http://www.fiercepharma.com/tags/astrazeneca">Astrazeneca</category>
 <category domain="http://www.fiercepharma.com/tags/china">China</category>
 <category domain="http://www.fiercepharma.com/tags/developing-world">developing world</category>
 <category domain="http://www.fiercepharma.com/tags/eli-lilly">Eli Lilly</category>
 <category domain="http://www.fiercepharma.com/tags/emerging-markets">emerging markets</category>
 <category domain="http://www.fiercepharma.com/tags/ims-health">IMS Health</category>
 <category domain="http://www.fiercepharma.com/tags/india">India</category>
 <category domain="http://www.fiercepharma.com/tags/pharma-growth">Pharma growth</category>
 <category domain="http://www.fiercepharma.com/tags/plavix">Plavix</category>
 <category domain="http://www.fiercepharma.com/tags/risperdal">Risperdal</category>
 <category domain="http://www.fiercepharma.com/tags/seroquel">Seroquel</category>
 <category domain="http://www.fiercepharma.com/tags/singulair">Singulair</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Wed, 16 Apr 2008 06:59:56 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8852 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>Judge wary of certifying Zyprexa classes</title>
 <link>http://www.fiercepharma.com/story/judge-wary-of-certifying-zyprexa-classes/2008-04-14?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description> Score one for Eli Lilly in federal court. A district judge says he probably won&#039;t give class-action status to patients and insurers who paid for Zyprexa for FDA-approved uses. And he doesn&#039;t expect &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/judge-wary-of-certifying-zyprexa-classes/2008-04-14&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/judge-wary-of-certifying-zyprexa-classes/2008-04-14#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/eli-lilly">Eli Lilly</category>
 <category domain="http://www.fiercepharma.com/tags/lawsuits">lawsuits</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Mon, 14 Apr 2008 06:59:57 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8839 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>If J&amp;J misled FDA, can patients sue?</title>
 <link>http://www.fiercepharma.com/story/if-jj-misled-fda-can-patients-sue/2008-04-07?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>Drug companies appear to be close to gaining a long-coveted prize: A shield against patient lawsuits. The Bush administration has been &lt;a &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/if-jj-misled-fda-can-patients-sue/2008-04-07&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/if-jj-misled-fda-can-patients-sue/2008-04-07#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/fda-approval">FDA approval</category>
 <category domain="http://www.fiercepharma.com/tags/johnson-johnson">Johnson &amp;amp; Johnson</category>
 <category domain="http://www.fiercepharma.com/tags/lawsuit">lawsuit</category>
 <category domain="http://www.fiercepharma.com/tags/lawsuits">lawsuits</category>
 <category domain="http://www.fiercepharma.com/tags/ortho-evra">Ortho Evra</category>
 <category domain="http://www.fiercepharma.com/tags/preemption">preemption</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Mon, 07 Apr 2008 06:59:57 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8803 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>Forbes to Big Pharma: Fess up</title>
 <link>http://www.fiercepharma.com/story/forbes-to-big-pharma-fess-up/2008-04-04?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. If the controversial Enhance study had proven Vytorin &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/forbes-to-big-pharma-fess-up/2008-04-04&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/forbes-to-big-pharma-fess-up/2008-04-04#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/merck">Merck</category>
 <category domain="http://www.fiercepharma.com/tags/vioxx">Vioxx</category>
 <category domain="http://www.fiercepharma.com/tags/vytorin">Vytorin</category>
 <category domain="http://www.fiercepharma.com/tags/zocor">Zocor</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Fri, 04 Apr 2008 07:59:55 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8794 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>Lilly&#039;s Lechleiter: &#039;We&#039;re a biotech&#039;</title>
 <link>http://www.fiercepharma.com/story/lilly-s-lechleiter-we-re-a-biotech-/2008-03-31?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>Tomorrow is the &lt;A href=&quot;http://www.fiercepharma.com/story/lilly-joins-pharmas-new-ceo-club/2007-12-18&quot;&gt;first day on the CEO job&lt;/a&gt; for Eli Lilly&#039;s John Lechleiter (&lt;A &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/lilly-s-lechleiter-we-re-a-biotech-/2008-03-31&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/lilly-s-lechleiter-we-re-a-biotech-/2008-03-31#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/eli-lilly">Eli Lilly</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Mon, 31 Mar 2008 07:59:54 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8765 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>ALSO NOTED:  Pre-emption fears helped spur Zyprexa deal; U.K. implant makers charge U.S. market;</title>
 <link>http://www.fiercepharma.com/story/also-noted-pre-emption-fears-helped-spur-zyprexa-deal-u.k.-implant-makers-c/2008-03-27?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>&amp;gt; Scratching your head over the Zyprexa settlement in Alaska? Apparently, the prospect of a Supreme Court ruling that might sweep away state pharma suits helped spur the agreement. &lt;A &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/also-noted-pre-emption-fears-helped-spur-zyprexa-deal-u.k.-implant-makers-c/2008-03-27&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/also-noted-pre-emption-fears-helped-spur-zyprexa-deal-u.k.-implant-makers-c/2008-03-27#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/janet-woodcock">Janet Woodcock</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Thu, 27 Mar 2008 07:59:50 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8750 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>Lilly, Alaska settle Zyprexa suit for $15M</title>
 <link>http://www.fiercepharma.com/story/lilly-alaska-settle-zyprexa-suit-for-15m/2008-03-26?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>One down, more than a dozen to go. &lt;A href=&quot;http://www.fiercepharma.com/story/lilly-gears-up-for-alaska-s-zyprexa-trial/2008-03-06&quot;&gt;Eli Lilly agreed to settle with the State of Alaska&lt;/a&gt;, promising &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/lilly-alaska-settle-zyprexa-suit-for-15m/2008-03-26&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/lilly-alaska-settle-zyprexa-suit-for-15m/2008-03-26#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/eli-lilly">Eli Lilly</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Wed, 26 Mar 2008 07:59:56 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8746 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>Judge: FDA can&#039;t police drugs alone</title>
 <link>http://www.fiercepharma.com/story/judge-fda-can-t-police-drugs-alone/2008-03-24?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>As Eli Lilly went up to bat in the big &lt;A href=&quot;http://www.fiercepharma.com/story/lilly-gears-up-for-alaska-s-zyprexa-trial/2008-03-06?utm_medium=nl&amp;amp;utm_source=link&quot;&gt;Zyprexa trial in Alaska&lt;/a&gt;, &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/judge-fda-can-t-police-drugs-alone/2008-03-24&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/judge-fda-can-t-police-drugs-alone/2008-03-24#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/diabetes">Diabetes</category>
 <category domain="http://www.fiercepharma.com/tags/drug-safety">drug safety</category>
 <category domain="http://www.fiercepharma.com/tags/eli-lilly">Eli Lilly</category>
 <category domain="http://www.fiercepharma.com/tags/fda">FDA</category>
 <category domain="http://www.fiercepharma.com/tags/lawsuits">lawsuits</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Mon, 24 Mar 2008 07:59:55 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8731 at http://www.fiercepharma.com</guid>
</item>
<item>
 <title>Did Lilly chief support off-label promos?</title>
 <link>http://www.fiercepharma.com/story/did-lilly-chief-support-off-label-promos/2008-03-17?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>You can bet incoming Eli Lilly CEO John Lechleiter (&lt;A href=&quot;http://www.fiercebiotech.com/pages/eli-lilly-ceo-john-c-lechleiter&quot;&gt;photo&lt;/a&gt;) spat out his Cheerios when he read the New York Times &lt;span class=&#039;read-more&#039;&gt;&lt;a href=&quot;http://www.fiercepharma.com/story/did-lilly-chief-support-off-label-promos/2008-03-17&quot;&gt;Read more...&lt;/a&gt;&lt;/span&gt;</description>
 <comments>http://www.fiercepharma.com/story/did-lilly-chief-support-off-label-promos/2008-03-17#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/eli-lilly">Eli Lilly</category>
 <category domain="http://www.fiercepharma.com/tags/zyprexa">Zyprexa</category>
 <pubDate>Mon, 17 Mar 2008 07:59:57 -0400</pubDate>
 <dc:creator>admin</dc:creator>
 <guid isPermaLink="false">8705 at http://www.fiercepharma.com</guid>
</item>
</channel>
</rss>
